Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients.
Interferon treatment of hepatitis C virus (HCV) infection in transplant recipients carries a high risk of rejection. We treated these patients with ultralow-dose interferon-alpha (1 x 10 units subcutaneously three times/week) plus ribavirin (600 mg/day) for 48 weeks. Treatment efficacy was evaluated by the changes of serum liver enzymes and viral load. A total of 11 patients were recruited for the study; biochemical response was obtained in all patients but one. Three patients terminated the therapy prematurely because of acute graft failure (one case) and urosepsis (two cases). Of the eight patients who completed a full course of therapy, five cleared HCV RNA at the end of treatment. Sustained biochemical and virologic responses were obtained in three patients (37.5%). Our regimen seemed to be relatively safe for renal transplant recipients with HCV. A significant portion of patients may achieve sustained biochemical and virologic responses.
Shu
Kuo-Hsiung
KH
Division of Nephrology, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan. khshu@vghtc.vghtc.gov.tw
Lan
Joung-Liang
JL
Wu
Ming-Ju
MJ
Cheng
Chi-Hung
CH
Chen
Chen-Hsu
CH
Lee
Wen-Chin
WC
Chang
Horng-Rong
HR
Lian
Jong-Da
JD
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D016030:Kidney Transplantation; D008297:Male; D012367:RNA, Viral / Q000302:isolation & purification; D012254:Ribavirin / Q000627:therapeutic use*; D012449:Safety
D000998:Antiviral Agents; D016898:Interferon-alpha; D012367:RNA, Viral; D012254:Ribavirin